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The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML) patients
using a dosing schedule that achieves potent but transient BCR-ABL inhibition. In vitro, transient potent
BCR-ABL inhibition with either dasatinib or imatinib is cytotoxic to CML cell lines, as is transient potent
EGFR inhibition with erlotinib in a lung cancer cell line. Cytotoxicity correlates with the magnitude as well
as the duration of kinase inhibition. Moreover, cytotoxicity with transient potent target inhibition is equivalent
to prolonged target inhibition and in both cases is associatedwith BIM activation and rescued byBCL-2 over-
expression. In CML patients receiving dasatinib once daily, response correlates with the magnitude of BCR-
ABL kinase inhibition, thereby demonstrating the potential clinical utility of intermittent potent kinase inhibitor
therapy.INTRODUCTION
A general assumption in the development of small-molecule ty-
rosine kinase inhibitors (TKIs) for cancer therapy is that clinical
success is likely to require prolonged target inhibition. For this
reason, drug discovery efforts generally select compounds
with longer half-lives for clinical development. These drugs are
typically administered on a schedule that is predicted to result
in continuous target inhibition, with the dose defined by tolerabil-
ity as well as clinical activity. The oral ABL kinase inhibitor imati-
nib, which is now a frontline therapy for chronicmyeloid leukemia
(CML), confers prolonged inhibition of the BCR-ABL kinase as
measured in the peripheral blood cells of CML patients 24 hr af-
ter a single dose. Imatinib has a half-life of 18 hr, as well asCa long-acting metabolite with a half-life of 40 hr (Druker et al.,
2001; Peng et al., 2004). Therefore, the dose and schedule com-
monly used for CML therapy produces nearly continuous target
inhibition. Other approved TKIs are known to have similarly long
half-lives in patients (erlotinib 36 hr, gefitinib 48 hr, lapatinib
24 hr, sunitinib 40–60 hr, sorafenib 25–48 hr) and are thus
predicted to provide prolonged target inhibition (Burris et al.,
2005; Cohen et al., 2004; Goodman et al., 2007; Johnson
et al., 2005; Kane et al., 2006).
Dasatinib is a second-generation ABL kinase inhibitor with
greater potency relative to imatinib in vitro that is effective in
CML patients who fail imatinib therapy (Shah et al., 2004; Talpaz
et al., 2006). Pharmacokinetic analysis performed during clinical
development revealed a short serum half-life for dasatinibSIGNIFICANCE
All previously approved tyrosine kinase (TK) inhibitors have prolonged half-lives in patients, resulting in continuous target
inhibition. Here we show that the BCR-ABL inhibitor dasatinib can achieve deep clinical remissions in chronic myeloid leu-
kemia patients using a dosing schedule that achieves transient potent BCR-ABL inhibition. Transient potent EGFR inhibition
is similarly effective against a lung cancer cell line in vitro. The kinetics of cell death and activation of the proapoptotic pro-
tein BIM observed with transient potent kinase inhibition are identical to prolonged target inhibition. These findings dem-
onstrate a critical reliance upon tonic TK activity for cell survival in two TK-associated malignancies and provide compelling
rationale for the clinical development of compounds capable of achieving potent kinase inhibition, irrespective of biological
half-life.ancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Inc. 485
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avoid the potential for long periods of uninhibited BCR-ABL
kinase activity, the phase I dosing schedule was amended to
include patients treated twice daily in parallel with those treated
once daily. Surprisingly, equivalent clinical response rates
were observed in 40 patients treated either once or twice daily,
including nearly 50%with complete cytogenetic remission (Phil-
adelphia chromosome undetectable in a standard metaphase
analysis) (Talpaz et al., 2006). Recently, a randomized clinical
trial comparing once-daily to twice-daily dosing of dasatinib in
CML showed equivalency in obtaining clinical responses and
improved tolerability and progression-free survival in patients
treated once daily, leading to a change in the approved
frequency of administration from twice daily to once daily (Shah
et al., 2008).
The clinical experience with dasatinib in CML challenges the
conventional wisdom that TKIs must achieve nearly continuous
target inhibition for maximal clinical impact. We sought to deter-
mine the relationship between time and depth of kinase inhibition
in vitro as well as in clinical trial experience and to characterize
the molecular mechanism whereby potent transient kinase
inhibition achieves cytotoxicity in cancer cells associated with
activated tyrosine kinases.
Figure 1. Transient but Potent BCR-ABL Inhibitor
Therapy Is Sufficient to Kill CML Cells
(A) Pharmacokinetic and pharmacodynamic assessment of
dasatinib in chronic myeloid leukemia (CML) patients.
Left: immunoblot using a pan-CRKL antibody of peripheral
blood mononuclear cell (PBMC) whole-cell lysates obtained
from five CML patients at the times listed following inges-
tion of the initial dose of dasatinib. Right: plasma concen-
trations of dasatinib determined by high-pressure liquid
chromatography (HPLC) in the same five CML patients
at the times listed following ingestion of the initial dose of
dasatinib.
(B) Normalized number of viable K562 cells following varying
durations of exposure to the concentrations of dasatinib
and imatinib indicated. Viable cell count was performed in
triplicate 48 hr after initial exposure to tyrosine kinase inhibi-
tor. Error bars represent standard deviation.
(C) Transient exposure to dasatinib achieves short-term
tyrosine kinase inhibition. Left: BCR-ABL kinase activity as
assessed by FACS-based phospho-CRKL analysis using
a phospho-CRKL-specific antibody in K562 cells exposed
to 100 nM dasatinib for 20 min. Right: phosphotyrosine con-
tent before and after exposure of K562 cells to 100 nM dasa-
tinib for 0.3 hr as assessed by anti-p-BCR-ABL antibody
(Y177) or anti-phosphotyrosine (p-Y) antibody (pY100). Anti-
ABL antibody serves as loading control. Time following initia-
tion of drug exposure is listed.
RESULTS
Efficacy of Transient Kinase Inhibition
The clinical success of once-daily dasatinib cou-
pled with its short serum half-life implies that inter-
mittent inhibition of BCR-ABL kinase activity is
sufficient for clinical response. To formally address
this question, we determined the magnitude of
BCR-ABL inhibition in patients treated once daily
with dasatinib at various times after administration of the initial
dose. A number of strategies have been used to measure
BCR-ABL kinase activity in the clinic, including tyrosine phos-
phorylation of downstream BCR-ABL substrates such as CRKL
and STAT5 as well as phosphotyrosine content of BCR-ABL.
CRKL phosphorylation has emerged as the most compelling
readout to date based on the specificity of this signal for BCR-
ABL activity as well as the reproducibility and reliability of the as-
say (Druker et al., 2001; Gorre et al., 2001). Phospho-BCR-ABL
content has been technically challenging to measure in patient
samples due to protein degradation after extraction of primary
CML cells, whereas STAT5 is problematic due to a number of
BCR-ABL-independent stimuli that can lead to its phosphoryla-
tion. In dasatinib-treated patients from five different dose
cohorts treated in a phase I study (Talpaz et al., 2006), CRKL
phosphorylation was diminished 4 hr after the initial dose in
a dose-dependent manner but was largely restored by 8 hr, co-
incident with the decline in dasatinib serum levels measured in
these same patients (Figure 1A). Therefore, as predicted by its
pharmacokinetic profile, dasatinib achieves transient inhibition
of BCR-ABL when taken once daily.
To model the clinical experience of transient BCR-ABL inhibi-
tion in vitro, we treated CML cells (K562) with 100 nMdasatinib or486 Cancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Inc.
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followed by drug washout and replating of cells in media without
drug. These TKI concentrations were chosen to mirror peak
serum levels achieved in patients using clinically effective doses.
Remarkably, when compared with mock-treated cells, only
about 10% of the cells treated with dasatinib for just 1 hr were
alive when assessed at 48 hr, whereas 24 hr of treatment was re-
quired to achieve comparable levels of cytotoxicity with imatinib
(Figure 1B, left panel). However, a higher imatinib concentration
(32.5 mM), chosen to match the in vitro ABL-inhibitory potency
of 100 nM dasatinib, was as effective as dasatinib in killing CML
cells after 1 hr of treatment. Indeed, similar levels of cytotoxicity
(90%) were seen with both drugs after exposure times as short
as 20min (Figure 1B, right panel), which we subsequently refer to
as ‘‘high-dose pulse’’ therapy. BCR-ABL kinase activity, mea-
sured by flow cytometry using a phospho-CRKL-specific anti-
body, recovered within hours of drug washout after high-dose
pulse dasatinib treatment, documenting that potent BCR-ABL in-
hibitionwas indeed transient asobserved inCMLpatients treated
once daily. Similar results were obtained by direct assessment of
overall BCR-ABL phosphotyrosine content (using a global phos-
photyrosine antibody) or specifically at Y177 (Figure 1C).
Figure 2. Cytotoxicity of High-Dose Pulse ABL and
EGFR Kinase Inhibitor Treatment Is Target Dependent
(A) Normalized cell viability (assessed at 48 hr in triplicate) of
BCR-ABL-negative (HL-60, NB-4) and BCR-ABL-positive
(KU-812) cell lines following high-dose pulse exposure to
dasatinib or imatinib.
(B) Normalized cell viability (assessed at 48 hr in triplicate)
in BCR-ABL-positive K562 cells and in BCR-ABL/T315I
K562 cells following continuous low-dose or high-dose pulse
dasatinib or imatinib.
(C) Left: normalized cell viability (assessed at 72 hr in triplicate)
of erlotinib-sensitive (HCC827) and -insensitive (H1975-2)
non-small cell lung cancer cell lines exposed to the indicated
concentrations of erlotinib for the indicated durations of time.
Right: immunoblot of phospho-EGFR (Y1068) recovery follow-
ing washout of 10 mM erlotinib. Total EGFR and actin immuno-
blots confirm adequate protein loading.
Error bars represent standard deviation.
Dasatinib inhibits a broader range of kinases
than imatinib (Carter et al., 2005), and both drugs
are likely to have additional off-target effects
when used at high concentrations, raising the
possibility that the cytotoxicity observed after
high-dose pulse therapy is not specific. Two lines
of evidence suggest that this is not the case.
First, high-dose pulse therapy did not impair the
growth of two BCR-ABL-negative human myeloid
leukemia cell lines, HL-60 and NB-4, but was cyto-
toxic in another BCR-ABL-positive leukemia cell
line, KU-812 (Figure 2A). In addition, K562 cells
engineered to express the BCR-ABL/T315I muta-
tion, which confers a high degree of resistance to
both imatinib and dasatinib (Shah et al., 2004),
were no longer sensitive to high-dose pulse
therapy (Figure 2B). As expected, we saw no
modulation of CRKL phosphorylation in the T315I-
expressing K562 cells or in BCR-ABL-negative leukemic cell
lines after exposure to high-dose dasatinib or imatinib (data
not shown).
Notably, the cytotoxicity of high-dose pulse TKI treatment is
not unique to BCR-ABL-containing CML cell lines, as similar
results were obtained with the EGFR inhibitor erlotinib in
EGFR-dependent lung cancer cell lines. HCC827 lung cancer
cells, which harbor an EGFR-activating exon 19 deletion as
well as EGFR amplification (Amann et al., 2005), were equally
sensitive to 20 min treatment with 10 mM erlotinib as to contin-
uous exposure to 1 mM erlotinib for 72 hr. Similar to phospho-
CRKL levels in CML cells treated with ABL inhibitors, phos-
pho-EGFR levels were substantially reduced after 20 min but
recovered within hours of drug washout (Figure 2C). As with
the ABL inhibitors, the effect of high-dose pulse exposure
appears to be specific as evidenced by the observation that
high-dose pulse erlotinib had no effect on H1975-2 lung cancer
cells, which contain the erlotinib-resistant EGFR T790M kinase
domain mutation in addition to the activating L858R mutation
(Pao et al., 2005). As expected, no change in EGFR phosphor-
ylation was observed in H1975-2 cells after high-dose pulse
erlotinib (data not shown).Cancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Inc. 487
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Cytotoxicity
Although the 100 nM concentration of dasatinib used in the high-
dose pulse therapy experiments mimics peak serum levels
achieved in patients, much lower concentrations (0.5–1 nM
IC50) induce cytotoxicity in vitro with prolonged exposure
(Shah et al., 2004). Since the effect of high-dose pulse ABL inhib-
itor therapy is BCR-ABL dependent, this begs the question of
whether low concentrations might achieve similar levels of cyto-
toxicity after transient exposure or whether duration of treatment
is an important variable under these conditions. To address this
question, we exposed CML cells to eight different concentra-
tions of either imatinib or dasatinib for treatment times varying
from 20min to 48 hr. Cytotoxicity was scored at 48 hr regardless
of treatment duration.
The results establish a relationship between concentration
and treatment duration (Figure 3A). Cytotoxicity approached
100 percent in cells exposed continuously to 0.5 or 1 nM dasati-
nib but was substantially diminished with shorter exposure
times. Similar results were observed using concentrations of im-
atinib (1 mM) that match those used in earlier studies of continu-
ous imatinib exposure in CML cells (Druker et al., 1996). Of note,
12 hr of treatment at these concentrations was insufficient to in-
Figure 3. Magnitude and Duration of Kinase Inhibition
Determines Cytotoxicity
(A) Normalized cell viability (assessed at 48 hr) of K562 cells
exposed to a range of concentrations of dasatinib (left) and
imatinib (right) for varying durations of time in triplicate. Error
bars represent standard deviation.
(B) Assessment of BCR-ABL kinase activity in K562 cells
through analysis of phospho-CRKL and phospho-STAT5
following treatment for 20 min with varying concentrations of
dasatinib (left) and imatinib (right).
duce cell death (measured at 48 hr), whereas longer
treatment periods led to an increasingly larger
fraction of dead cells. In contrast, high concentra-
tions of either drug (50–100 nM dasatinib or 12.5–
32.5 mM imatinib) were nearly 100% cytotoxic after
much shorter treatment intervals (from 20 min to
4 hr). Intermediate concentrations (2.5–25 nM da-
satinib, 2.5–10 mM imatinib) showed progressively
more cytotoxicity with extended treatment times.
These data establish a relationship between con-
centration and treatment duration such that high-
dose pulse therapy and low-dose continuous
therapy confer equivalent cytotoxicity to CML cells.
To determine whether the concentration-depen-
dent effect of ABL inhibitors on cytotoxicity is
correlated with kinase inhibition, we used several
assays to assess BCR-ABL kinase activity in
K562 cells 20 min after drug exposure over the
range of concentrations studied above. Phospho-
CRKL content measured by flow cytometry was
reduced in a concentration-dependent manner in
cells treated with either dasatinib or imatinib, but
this effect was clearly measurable only at higher
concentrations (R10 nM dasatinib,R2.5 mM imati-
nib). Surprisingly, we were unable to detect a substantial reduc-
tion in phospho-CRKL content at lower concentrations, even
though these same concentrations confer substantial antiproli-
ferative activity after prolonged continuous exposure. Similar
results were obtained when phospho-CRKL was measured at
later time points (up to 24 hr after drug exposure) or by western
blot analysis using a pan-CRKL antibody that quantifies phos-
pho-CRKL through mobility shift analysis of CRKL isoforms
(data not shown), arguing against an accumulation of BCR-
ABL inhibition over time as the explanation for this apparent
paradox. In contrast, phospho-STAT5 content as measured by
flow cytometry was substantially reduced by both drugs at
the very lowest concentrations tested, consistent with published
western blot data (Kindler et al., 2003), with apparent saturation
of the assay at the second or third concentration level. The phos-
photyrosine content of BCR-ABL, as measured by western
blot using a global phosphotyrosine antibody, was similarly
reduced in a dose-dependent manner (see Figure S1 available
online). In summary, BCR-ABL kinase activity is inhibited in
a concentration-dependent fashion over the range of concentra-
tions studied here, indicating that the cytotoxicity of high-dose
pulse exposure to ABL TKIs correlates with the magnitude of
target inhibition.488 Cancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Inc.
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displayed strikingly different abilities to measure BCR-ABL
kinase inhibition was unexpected. Phospho-STAT5 appears to
be highly sensitive to the lowest concentrations used here, which
correspond to the IC50s for growth inhibition caused by continu-
ous drug exposure, whereas phospho-CRKL detects kinase
inhibition at the highest concentrations where suppression of
the phospho-STAT5 signal is saturated. One potential explana-
tion for these differences could be in the relative pools of phos-
phorylated versus nonphosphorylated STAT5 and CRKL in CML
cells at baseline. If only a small fraction of STAT5 molecules are
phosphorylated in K562 cells at steady state, then relatively
modest inhibition of BCR-ABL activity could be sufficient to dra-
matically shift the entire pool of phospho-STAT5. To address this
possibility, we exposed cells to the nonspecific tyrosine phos-
phatase inhibitor pervanadate for 30 min in an attempt to maxi-
mally increase the pools of phosphorylated STAT5 and CRKL.
Flow cytometric analysis showed a substantial (10-fold) increase
in basal phospho-STAT5 content with relatively modest effects
on phospho-CRKL content (Figure S2), consistent with the hy-
pothesis that a much greater fraction of CRKL is phosphorylated
(as previously demonstrated by western blot analysis) in CML
cells relative to STAT5. The mechanism for these differences in
the sizes of these phosphosubstrate pools is unknown but could
be based on differential efficiency of substrate phosphorylation
(CRKL, but not STAT5, is physically associated with BCR-ABL)
(Ren et al., 1994; Senechal et al., 1998) or differential action of
STAT5 versus CRKL phosphatases. Regardless, these data
reveal unappreciated complexities in using substrate phosphor-
ylation to measure target inhibition and argue for evaluation of
multiple endpoints to ensure that an adequate dynamic range
is assessed.
Rapid and Irreversible Engagement of the BIM/BCL-2
Pathway by High-Dose Pulse Therapy
The fact that 20 min of a high concentration of ABL kinase inhib-
itor treatment was sufficient to confer cytotoxicity at 48 hr sug-
gested that high-dose pulse therapy leads to irreversible induc-
tion of a cell death program. Despite allowing 7 days for recovery
in imatinib-free medium, no viable cells were detected following
high-dose pulse imatinib (Figure S3). To search for potential
differences in the onset of cell death, we measured caspase-3
activation and annexin V staining at various times after treatment
with high-dose pulse versus low-dose continuous dasatinib. The
earliest evidence for cell death detected by either assay was
at 24 hr, with no clear difference between the two treatment
regimens. Furthermore, continuous exposure of cells to a high
concentration of dasatinib revealed similar kinetics of cell death,
indicating that no further gain in cytotoxicity is achieved through
continuous potent target inhibition (Figure S4). We therefore
turned to earlier measures of engagement of the apoptotic path-
way, such as the BH3-only protein BIM, whose expression is in-
creased within hours of continuously applied imatinib treatment
(Kuroda et al., 2006). As expected, BIM protein levels were
increased and migrated with faster mobility (due to dephosphor-
ylation) as early as 2 hr after continuous treatment with 1 nM
dasatinib, and this was maintained for 48 hr. At later time points,
levels of the antiapoptotic proteins BCL-2 and BCL-XL were
modestly reduced, whereas no change was observed inCMCL-1 levels (Figure 4A). Essentially identical results were
obtained using high-dose pulse dasatinib, indicating that the ap-
optotic machinery is equally engaged early by both treatment
regimens, and with imatinib (Figure S5).
It is unlikely that BIM induction at 2 hr is sufficient to induce cell
death based on our earlier time-course studies (Figure 3A) show-
ing that at least 8 hr of low-dose dasatinib treatment is required
for substantial cytotoxicity. We therefore conducted a low-dose
pulse experiment (6 hr of treatment with 1 nM dasatinib, which
Figure 4. Kinetics of BIM Induction after High-Dose Pulse versus
Low-Dose Continuous Dasatinib Exposure
(A) Kinetic assessment of select proapoptotic and antiapoptotic proteins in
K562 cells treatedwith low-dose continuous (left) or high-dose pulse (right) da-
satinib. Lysates were prepared at varying times after initiation of drug exposure
as indicated and examined by immunoblot using antibodies specific for BIM,
BCL-2, BCL-XL, MCL-1, and actin.
(B) Effect of low-dose dasatinib treatment on select proapoptotic and antia-
poptotic proteins in K562 cells treated for 6 hr.
(C) Left: immunoblot of K562/BCL-2 whole-cell extract demonstrating produc-
tion of BCL-2 protein. Right: effect of ectopic BCL-2 overexpression on
normalized cell viability of K562 cells treated with either 1 nM dasatinib contin-
uously or 100 nM dasatinib for 20 min. Percentage of viable cells was deter-
mined (in triplicate) 48 and 72 hr after initial drug exposure and normalized
to mock-treated cells. Error bars represent standard deviation.ancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Inc. 489
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ibility of BIM induction. Indeed, BIM levels and mobility were re-
stored to levels seen in untreated cells within 2 hr of drug removal
(Figure 4B), indicating that BIM induction is fully reversible after
low-dose treatment but irreversible after high-dose treatment.
Consistent with published data on imatinib (Kuroda et al., 2006),
cell death induced by continuous exposure of CML cells to dasa-
tinib was BCL pathway dependent, as shown by rescue of viabil-
ity in K562 cells engineered to overexpress BCL-2. Notably, the
cytotoxicity of high-dose pulse dasatinib was also fully reversed
by BCL-2 overexpression (Figure 4C), suggesting that the two
treatment regimens kill cells by similar mechanisms.
BCR-ABL Kinase Inhibition Is Associated
with Clinical Response
An important clinical implication of the high-dose pulse therapy
experiments is that the magnitude of BCR-ABL inhibition should
impact the degree of clinical response for a drug with the short
half-life of dasatinib. Specifically, the immunoblot and flow cy-
tometry studies in CML cell lines suggest that >90% BCR-ABL
inhibition is required for the irreversible cytotoxicity of high-
dose pulse therapy. To determine whether this relationship
exists in patients, wemeasuredCRKL phosphorylation in periph-
eral blood 4 hr after the first dose in the 21 chronic-phase CML
patients treated in the phase I clinical trial who received once-
daily dasatinib (Talpaz et al., 2006) and correlated the degree
of inhibition with clinical outcome (Figure 5). There was a statisti-
cally significant correlation between reduction of CRKL phos-
Figure 5. Correlation between BCR-ABL Inhibition 4 hr after Initial
Dose of Dasatinib and Best Observed Outcome at that Dose of Drug
Each diamond represents the value obtained for an individual patient. CHR
refers to complete hematologic response. Cytogenetic response is defined
as a decline in the number of BCR-ABL-positive bonemarrowmetaphases fol-
lowing initiation of dasatinib. CCyR refers to complete cytogenetic response
(no evidence of BCR-ABL in at least 20 bone marrow metaphases). The phos-
phorylated and nonphosphorylated forms of CRKL were detected by immuno-
blot using a pan-CRKL antibody as in Figure 1A and quantified by ImageQuant.
Percent phospho-CRKL (% p-CRKL) was determined using the equation
p-CRKL/(p-CRKL + CRKL) 3 100 = % p-CRKL. By Kruskal-Wallis one-way
analysis of variance, the overall null hypothesis that the distribution is the
same among the three response groups was rejected (p = 0.0012). Comparing
the p-CRKL values of patients with complete cytogenetic response to all
others yields a two-sided p value of 0.0004 (rank-sum test).490 Cancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Incphorylation and magnitude of clinical response (hematologic or
cytogenetic; p = 0.0012). Notably, the patients with the best
responses (complete cytogenetic remission) had >90% reduc-
tion in CRKL phosphorylation (p = 0.0004).
DISCUSSION
Early in the development of targeted cancer therapies, much
attention was devoted to the identification of compounds with
relative specificity for the intended drug target and pharmaco-
logic properties that maximize the probability of sustained target
engagement using various measurements of target inhibition.
These principles have resulted in the clinical success of inhibitors
against a range of targets such as ABL, KIT, EGFR, HER2, and
VEGFR, all of which are dosed using schedules derived to
achieve sustained kinase inhibition while avoiding toxicity.
Based on this rationale, the clinical development of dasatinib
initially proceeded using a twice-daily dosing schedule due to
its relatively short half-life, with the goal of providing continuous
target coverage. However, we now know that the clinical benefit
of dasatinib is equivalent when dosed once daily, and, impor-
tantly, tolerability is superior to the twice-daily schedule (Shah
et al., 2008).
The clinical experience with dasatinib begs the question of
whether sustained target inhibition should remain a driving prin-
ciple in the development of targeted cancer therapies or whether
intermittent target inhibition may be sufficient. Here we demon-
strate that potent inhibition of BCR-ABL kinase activity is indeed
transient in CML patients treated once daily but that maximal
clinical benefit is associated with maximal BCR-ABL inhibition.
We show that the same principle applies to CML cell lines grown
in culture and extends more broadly to other kinase-dependent
tumors such as EGFR mutant lung cancer. Of note, a small
single-institution study of intermittent (weekly) high-dose ther-
apy with erlotinib reported at least one clinical response in an
EGFRmutant lung cancer patient (Milton et al., 2006). By exam-
ining a broad range of doses and treatment intervals, we found
that both the magnitude and duration of target inhibition are
linked to cytotoxicity in these kinase-dependent models, sug-
gesting that an area under the curve (AUC) of target engagement
(conceptually analogous to an AUC of drug exposure) could be
a primary determinant of biological sensitivity.
The 20 min high-dose pulse exposure described here repre-
sents an extreme application of the transient therapy concept
and raises several questions, including whether bioactivity is
solely explained by inhibition of the intended target. Despite
the fact that the high concentrations of dasatinib we selected
can be achieved clinically, many additional targets are certainly
inhibited at these doses. But several lines of evidence argue
for specificity of the biological effect: (1) cytotoxicity is observed
only in kinase-dependent models expressing the relevant target;
(2) sensitive cells are rescued from cell death by drug-resistant
mutants of the target (T315I for BCR-ABL, T790M for EGFR);
and (3) similar bioactivity is seen with chemically distinct inhibi-
tors, which would be expected to differ in their off-target activi-
ties at high doses. For these reasons, we favor a model whereby
the biological activity of high-dose pulse therapy is explained by
the potent suppression of the intended kinase target. In the
absence of a pure inhibitor, we cannot exclude the possibility.
Cancer Cell
Brief Potent Kinase Inhibition Causes Apoptosisthat efficacy is explained by combined effects on the target
kinase as well as other kinases.
Another considerationwith the high-dosepulsemodel relates to
the recovery of kinase activity after drug washout. Although we
document restoration of BCR-ABL (and EGFR) phosphotyrosine
content within hours, we cannot exclude the possibility of a small
degree of residual kinase inhibition that is undetectable by these
assays. Similarly, patients treated with once-daily dasatinib
show rapid recovery of BCR-ABL activity (relative to imatinib),
butasmall amountof residual inhibitionmaypersist since thephar-
macokinetic profile shows a delayed terminal elimination phase
(similar to most oral small-molecule drugs). The remarkable find-
ing—in the cell culturemodel and in patients—is that potent target
inhibition remains effective even if it is achieved only transiently.
Themechanism of cell death induced by high-dose pulse ther-
apy needs further exploration but appears to be remarkably
similar to that observed with low-dose continuous therapy.
With both regimens, similar increases in BIM protein levels are
observed within 2 hr of drug exposure, and levels of BCL-2
and BCL-XL are gradually reduced with similar kinetics. One im-
portant distinction is that BIM induction by low-dose exposure is
reversible after at least 6 hr of treatment, whereas induction by
high-dose exposure is irreversible after only 20 min. This result
is consistent with a model whereby a threshold level of kinase in-
hibition must be exceeded to commit cells to death and that
threshold is determined by both the magnitude and duration of
target inhibition. The kinetics of BIM induction (sustained versus
unsustained) might serve as an early biomarker for defining
this threshold. In the context of larger discussions on the phe-
nomenon of oncogene addiction (Weinstein, 2002), it has been
proposed that kinase inhibitors are effective against oncogene-
addicted cancers due to the more rapid decay of oncogene-
mediated prosurvival versus proapoptotic signals following
pharmacologic inactivation of the oncogene (Sharma et al.,
2006). Evidence for the ‘‘oncogenic shock’’ model comes from
cells exposed continuously to concentrations of kinase inhibitors
comparable to the low-dose continuous treatments used here. It
is possible that the cytotoxicity of high-dose pulse exposure
could be explained by a similar oncogenic shock model.
From the clinical perspective, the fact that efficacy was not
compromised in the examples studied here by high-dose pulse
therapy raises the question of whether a broader range of doses
and schedules should be considered in early-stage clinical trials
of targeted agents, particularly for compounds whose toxicity
profile might preclude continuous therapy. As illustrated by the
differential sensitivity of phospho-CRKL and phospho-STAT5
at reflecting BCR-ABL inhibition, the pharmacodynamic bio-
markers used to evaluate different dosing schedules will need
to be chosen carefully after consideration of several different
downstream readouts. With robust quantitative measures of
target inhibition in hand, it should also be possible to optimize
individual patient doses, balancing target inhibition with toxicity,
in pursuit of the goal of rational personalized cancer medicine.
EXPERIMENTAL PROCEDURES
Western Immunoblot of Cell Lysates from CML Patients
As specified by protocol, blood was obtained for pharmacokinetic and phar-
macodynamic studies from consenting CML patients enrolled in a UCLA Insti-Ctutional Review Board-approved phase I study of dasatinib. Blood samples for
pharmacodynamic studies were collected on cycle 1/day 1 at the following
time points relative to drug administration: predose, 4 hr, 8 hr, and 24 hr
(just prior to the day 2 dose) postdose. Peripheral blood mononuclear cell
(PBMC) isolation, preparation of whole-cell extracts, and CRKL immunoblot-
ting were performed as described previously (Gorre et al., 2001).
Pharmacokinetic Analysis of Dasatinib
Blood samples were collected on cycle 1/day 1 at the following time points rel-
ative to drug administration: predose, 30 min, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 5 hr,
6 hr, 8 hr, and 24 hr (just prior to the day 2 dose) postdose. Liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) was utilized for the quantita-
tion of dasatinib in 0.1 ml of human EDTA plasma using a Sciex API 3000
mass spectrometer (Applied Biosystems). After the addition of phosphoric
acid containing internal standard (200 ng/ml of plasma) to 0.1 ml of each qual-
ity control (QC) sample and calibration standard, the samples were loaded
onto an Oasis HLB mElution 96-well solid-phase extraction plate (Waters).
The compounds were eluted with 50 ml of methanol. After the addition of water
to the methanol eluate and vortexing, the extracts were injected into the
LC-MS/MS system. Chromatographic separation was achieved isocratically
on a Phenomenex Luna phenyl-hexyl analytical column (2 3 50 mm, 3 mm,
Phenomenex). The mobile phase contained formic acid, water, methanol,
and ammonium acetate. Detection was by positive ion electrospray-tandem
mass spectrometry. The standard curves, which ranged from 1 to 1000 ng/ml,
were fitted to a 1/x weighted quadratic regression model and converted to nM
units. The intra-assay precision was within 4.2% coefficient of variation (CV),
and interassay precision was within 3.0% CV for both analytes. The assay
accuracy was within ±4.5% of the nominal values for analytical QC samples.
For both analytes, at the lower limit of quantitation (LLOQ) of 1 ng/ml, the de-
viations of the predicted concentrations from the nominal value for all six LLOQ
samples were within ±9.0%.
Quantification of BCR-ABL Kinase Inhibition in CML Patients
4 hr after Dasatinib Administration
Lysates prepared from PBMCs isolated 4 hr after ingestion of the initial dose of
dasatinib were subject to immunoblotting with anti-CRKL antibody. The phos-
phorylated and nonphosphorylated forms of CRKL were detected using ECL
(GE Healthcare). Autoradiographs (Kodak) were imaged using a digital imager
(Bio-Rad) to generate TIFF files. The TIFF files were then analyzed with Image-
Quant v2003 software (GE Healthcare). Background was corrected. Percent
phospho-CRKL (% p-CRKL) was determined using the equation p-CRKL/(p-
CRKL + CRKL) 3 100 = % p-CRKL.
Tyrosine Kinase Inhibitors
Dasatinib was provided by Bristol-Myers Squibb, imatinib was provided by
Novartis Pharmaceuticals, and erlotinib was purified from tablets. Stocks of
20 mM dasatinib and 10 mM imatinib and erlotinib were prepared in DMSO
and stored at 80C.
Cell Lines, Drug Exposures, and Viability Determination
Cell lines were propagated in RPMI supplemented with 10% FCS, L-gluta-
mine, and penicillin/streptomycin. Exponentially growing cells were plated at
2 3 105 cells/ml and exposed in medium to varying concentrations of TKIs
prepared from stock solutions. For pulse conditions, cells were washed three
timeswith a volume of medium that consisted of 50%of the volume of the drug
exposure and replated in fresh medium without inhibitor at a final concentra-
tion of 2 3 105 cells/ml. Viability was assessed at 24, 48, and 72 hr after initial
exposure using trypan blue exclusion on a Vi-CELL XR (Beckman Coulter,
Inc.), and cell counts were normalized to mock-treated controls. Experiments
were performed in triplicate. K562/T315I and K562/BCL-2 cells were created
as follows. Cotransfection of MSCV-puroBCR-ABL/T315I (Gorre et al., 2001)
or pMIG/BCL-2 (Addgene Inc., deposited by S. Korsmeyer) with pCL-Ampho
into 293FT cells was performed, and the supernatant was removed after 48 hr
and filtered through a 0.45 mm filter. Spinoculation of K562 cells was followed
with selection of cells by puromycin (for MSCV-puroBCR-ABL/T315I) or by
sorting GFP-positive cells (for pMIG/BCL-2). HCC827 and H1975-2 cells,
kindly provided by W. Pao (Memorial Sloan-Kettering Cancer Center), were
cultured in 5% serum.ancer Cell 14, 485–493, December 9, 2008 ª2008 Elsevier Inc. 491
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Flow cytometry was performed with a LSR II (BD Biosciences) using standard
methods. Briefly, for phosphoprotein analysis, 5 3 105 cells per sample were
fixed using 3.2% paraformaldehyde and washed by adding 2 ml phosphate-
buffered saline (PBS) followed by gentle resuspension and centrifugation.
Cell pellets were aspirated and resuspended in methanol and stored overnight
at 20C. Cells were then rehydrated after a PBS wash by resuspending in
PBS with 4% FBS (incubation buffer). Cells were blocked after centrifugation
and aspiration by adding 0.5 mg Fcy III/II receptor antibody (BD Biosciences)
and incubating for 15 min at 4C. Cells were stained with 50 ml of an antibody
mix containing 1 ml primary phospho-CRKL antibody (Cell Signaling Technol-
ogy) in incubation buffer per sample; staining proceeded for 20 min at room
temperature. Cells were washed with buffer, aspirated, and stained with
0.125 mg anti-rabbit R-phycoerythrin secondary antibody (BioSource) and
10 ml primary conjugated phospho-STAT5 antibody (BD Biosciences) for
20 min at room temperature. Cells were washed once with PBS prior to collec-
tion. Annexin V and active caspase-3 staining was performed according to the
manufacturer (BD Biosciences.) Approximately 30,000 ungated events were
collected for each sample on a LSR II (BD Biosciences) and analyzed using
FlowJo software (Tree Star, Inc.). All phosphoflow analyses were performed
at least in triplicate and yielded similar results.
Phosphatase Experiments
Vanadate solutions were prepared using equimolar concentrations of sodium
orthovanadate (Sigma-Aldrich) and hydrogen peroxide (Fisher Scientific), and
cells were incubated in the presence of vanadate for 90min before fixation and
flow analysis.
Immunoblot of Cell Line Extracts
At the indicated time points, 5 3 106 cells were harvested, washed twice with
PBS, and lysed in 200 ml cell extraction buffer (Omnia) supplemented with
10 ml/ml protease and phosphatase inhibitors (inhibitor cocktails II and III,
Calbiochem). Each lysate (30 mg) was electrophoresed on a 10%Bis-Tris poly-
acrylamide gel using MES running buffer (NuPAGE). BIM, BCL-2, BCL-XL,
MCL-1, and actin were identified with Cell Signaling Technology antibodies.
Phospho-BCR-ABL was assessed using a phosphospecific antibody for
Y177 (Cell Signaling Technology), and BCR-ABL protein was identified with
anti-ABL antibody AB-3 (Oncogene Research Products) following electropho-
resis of cell lysates on a 3%–8% Tris-acetate gel. CRKL was identified with
anti-CRKL antibody (Santa Cruz Biotechnology). Phosphotyrosine was de-
tected using anti-phosphotyrosine antibodies (4G10, Upstate Biotechnol-
ogies; PY100, Cell Signaling Technology) as described previously (Gorre
et al., 2001).
SUPPLEMENTAL DATA
The Supplemental Data include five figures and can be found with this article
online at http://www.cancercell.org/supplemental/S1535-6108(08)00368-1.
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